Injection of Colon Carcinoma Patients with Autologous Irradiated Tumor Cells and Fibroblasts Genetically Modified to Secrete Interleukin-2 (IL-2): A Phase I Study. San Diego Regional Cancer Center, San Diego, California

This publication has 10 references indexed in Scilit:

• Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial.
  Journal of Clinical Oncology, 1993
• Cytokines: structure, function and synthesis
  Current Opinion in Immunology, 1990
• Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.
  The Journal of Experimental Medicine, 1990
• Gene Transfer into Humans — Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction
  New England Journal of Medicine, 1990
• Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
  Cell, 1990
• Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity.
  Proceedings of the National Academy of Sciences, 1989
• Murine interleukin-4 displays potent anti-tumor activity in vivo
  Cell, 1989
• Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice
  Immunology Letters, 1988
• New Approaches to the Immunotherapy of Cancer Using Interleukin-2
  Annals of Internal Medicine, 1988
• High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings
  JAMA, 1986